搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
腾讯网
14 小时
潜在“first-in-class”小分子达3期临床主要终点,双重机制提高镇痛效果
Tris ...
20 天
药明生物涨超3% 近日与中国生物制药就“First-in-Class”单抗达成研究 ...
药明生物(02269)涨超3%,截至发稿,涨3.69%,报17.42港元,成交额2.6亿港元。 消息面上,12月30日,药明生物宣布与中国生物制药达成研究服务合作协议,以支持其发现一款靶点未披露的“First-in-Class”单克隆抗体。根据协议,药明生物将通过抗体发现技术平台(如单B细胞技术平台)提供一体化研究服务,根据中国生物制药指定的靶点生成抗体,并进行先导抗体发现、优化以及可开发性评估等 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Hughes Fire prompts evacs
Trump pardons DC officers
San Antonio officers shot
Houston refinery closure
New panel to probe Jan. 6
Thai same-sex marriage law
NYC aesthetician charged
DOJ halts civil rights work
KKK flyers in Kentucky
Exits Quebec operations
'Bling Empire' star dies
Sues accuser for defamation
ACLU sues over deportations
Workers union reaches deal
Designates Houthis terrorist
Former NC judge dies
Songwriters HOF inductees
Jets hire Glenn as coach
Legendary guitarist dies
Curran to lead Secret Service
Weighs police conduct
Chevrolet Equinox EV recall
Loses bid for new trial
Remains of WI pilot ID'd
Launches bid for governor
Court: Elephants can't sue
Soda button reinstalled
Jan. 6 rioter arrested again
Ex-El Salvador pres dies
Nashville school shooting
Passes Laken Riley Act
反馈